Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

About this update from Kura Oncology, Inc.

[{"type":"image","alt":"Kura Oncology, Inc.","displaySize":"","headline":null,"caption":"Kura Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PJRX2TqLyUcTZckqR2nKgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a","width":300,"height":157}},"lazy":false},{"type":"text","content":"Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy","length":149,"tagName":"p"},{"type":"text","content":"Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST","length":99,"tagName":"p"},{"type":"text","content":"SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France.","length":475,"tagName":"p"},{"type":"text","content":"The data to be presented build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology (ESMO) Congress, where the combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile in patients with advanced renal cell carcinoma.","length":326,"tagName":"p"},{"type":"text","content":"IKCS Europe 2026 Presentation Details","length":37,"tagName":"p"},{"type":"text","content":"Title: Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) combined with cabozantinib (cabo) in clear cell renal cell carcinoma (ccRCC) patients after prior exposure to cabo: Preliminary Phase 1 results from FIT-001Abstract Session: 7Date: April 17, 2026Time: 3:30 p.m. – 4:30 p.m. CEST","length":297,"tagName":"p"},{"type":"text","content":"Virtual Investor EventKura will host a webcast and conference call on April 17, 2026, at 7:30 am PT / 10:30 am ET / 4:30 pm CEST featur...

More updates from Kura Oncology, Inc.